

BACKGROUND

- Neurologic involvement (NI) is common in ANCA-Associated Vasculitis (AAV), ranging from 22 to 54% in GPA, 34 to 72% in MPA, and up to 75% in EGPA
- NI in patients with AAV has a negative impact on multiple domains of illness and health-related quality of life (HRQoL)
- Most data on NI in AAV are derived from clinician-reported data
- This project assessed the prevalence and impact of NI on HRQoL in patients with AAV enrolled in the Vasculitis Patient-Powered Research Network (VPPRN), an online registry in which patients provide data

METHODS

- Patients with GPA, MPA, or EGPA enrolled in the VPPRN
- Data captured from 2014-2022 from patients at least 18 years old at enrollment
- Patient subsets were compared according to presence or absence of NI
- HRQoL assessments included several PROMIS domains:
 - Fatigue, Depression, Sleep Disturbance , Pain Interference, Physical Function, Social Isolation, and Anxiety
 - PROMIS measures generate T-scores with the mean T-score = 50 with a standard deviation of 10 in the reference population (U.S. general population)

RESULTS

Table 1. Demographics of patients with or without NI

Variable	All Patients (n=1465)	With Neurologic Involvement (n=901)	Without Neurologic Involvement (n=564)	P-value	N
Age at Diagnosis (years)	42.0 [28.0; 54.0]	45.0 [32.0; 56.0]	40.0 [22.0; 53.0]	0.032	211
Gender				0.426	1462
	Female	1025 (70.1%)	623 (69.3%)		
	Male	437 (29.9%)	276 (30.7%)	161 (28.6%)	
	Asian	28 (1.91%)	14 (1.55%)	14 (2.48%)	
Race	Black	19 (1.30%)	12 (1.33%)	7 (1.24%)	
	White	1335 (91.1%)	822 (91.2%)	513 (91.0%)	
	Other	83 (5.67%)	53 (5.88%)	30 (5.32%)	
Type of Vasculitis	EGPA	266 (18.2%)	121 (13.4%)	<0.001	1465
	GPA	985 (67.2%)	634 (70.4%)		
	MPA	214 (14.6%)	146 (16.2%)		
Disease Duration (years)	8.63 [4.88;13.8]	8.59 [4.72;13.3]	8.72 [5.21;15.1]	0.162	1213
ANCA-Positive	1123 (86.7%)	703 (88.7%)	420 (83.5%)	0.010	1296
Continuous variables presented as Mean (SD) or Median [P25, P75], categorical variables presented as N (column %).					


Table 2. Clinical characteristics of patients with or without NI

Variable	All Patients (n=1465)	With Neurologic Involvement (n=901)	Without Neurologic Involvement (n=564)	P-value	N
Constitutional Symptoms	994 (75.2%)	660 (81.5%)	334 (65.2%)	<0.001	1322
Musculoskeletal	1174 (83.0%)	815 (92.4%)	359 (67.5%)	<0.001	1414
Skin	838 (60.0%)	578 (67.5%)	260 (48.1%)	<0.001	1396
Mucous Membranes	515 (38.0%)	367 (44.9%)	148 (27.6%)	<0.001	1355
Eye	624 (45.4%)	401 (48.1%)	223 (41.2%)	0.015	1375
Ear, Nose, and Throat	1138 (83.1%)	751 (88.7%)	387 (74.1%)	<0.001	1369
Cardiovascular	123 (9.91%)	98 (13.7%)	25 (4.74%)	<0.001	1241
Gastrointestinal	37 (2.72%)	29 (3.55%)	8 (1.47%)	0.033	1362
Pulmonary	928 (66.0%)	616 (72.0%)	312 (56.8%)	<0.001	1405
Renal	905 (63.3%)	559 (63.8%)	346 (62.5%)	0.644	1430
Venous Thrombosis	187 (13.4%)	132 (15.7%)	55 (10.0%)	0.003	1393
Severity of Vasculitis	4.00 [1.00;5.00]	5.00 [2.00;6.00]	3.00 [0.00;5.00]	<0.001	1462
Continuous variables presented as Mean (SD) or Median [P25, P75], categorical variables presented as N (column %).					

Table 3. Prevalence of NI in patients with AAV enrolled in VPPRN is higher compared to major cohorts

	VPPRN N=1465	DCVAS* N= 955	VCRC N= 1368	P value
Patients with AAV	62%	28%	34%	<0.001
Patients with GPA	64%	19%	25%	<0.001
Patients with MPA	68%	23%	22%	<0.001
Patients with EGPA	46%	65%	67%	<0.001

*DCVAS included patients with vasculitic neuropathy only



CONCLUSIONS

- NI in AAV is common and is associated with significant reductions in HRQoL
- The prevalence of NI as reported by patients compared to physician-reported data is higher for GPA and MPA, but lower for EGPA
- Compared to patients without NI, patients with NI
 - Are older at the time of diagnosis of AAV
 - Are more often positive for ANCA
 - Have more different manifestations of AAV
 - Report greater severity of their vasculitis
- The rate of renal involvement is the same among patients with or without NI
- Patients with AAV report reduced HRQoL in almost all domains compared to a reference general population

The Vasculitis Patient-Powered Research Network received funding from
the Vasculitis Foundation and GlaxoSmithKline